Webster et al., 1987 - Google Patents

Cyclosporin A prevents suppression of delayed-type hypersensitivity in mice immunized with high-dose sheep erythrocytes.

Webster et al., 1987

View PDF
Document ID
2200509071776941700
Author
Webster L
Thomson A
Publication year
Publication venue
Immunology

External Links

Snippet

When administered intraperitoneally to mice 2 days before immunization with a tolerogenic dose (10 (9)) of sheep red blood cells (SRBC), cyclosporin A (CsA; 200 mg/kg) strikingly augmented 4-day delayed-type hypersensitivity (DTH) footpad reactions. These enhanced …
Continue reading at www.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Similar Documents

Publication Publication Date Title
Fiser et al. T-lymphocyte subsets in nephrotic syndrome
McCune et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus
LAWLEY et al. Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease
CA1333569C (en) Method of treatment for autoimmune diseases
MONACO et al. Some effects of purified heterologous antihuman lymphocyte serum in man
Capron et al. Tetrapeptides of the eosinophil chemotactic factor of anaphylaxis (ECF-A) enhance eosinophil Fc receptor
Thomson et al. Modification of delayed-type hypersensitivity reactions to ovalbumin in cyclosporin A-treated guinea-pigs.
Thomas et al. A heparin analogue with specific action on antithrombin III
Wahl et al. Leukapheresis in rheumatoid arthritis association of clinical improvement with reversal of anergy
US5208018A (en) Treatment of cachexia with interleukin 2
Thomson et al. Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse.
Andreoli et al. Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients
EP0670723B1 (en) Use of thioureleylenes and thiabendazole in autoimmune and inflammatory diseases of the skin
Denman et al. Suppression of Coombs-positive haemolytic anaemia in NZB mice by antilymphocyte globulin
Haruta et al. Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats
Webster et al. Cyclosporin A prevents suppression of delayed-type hypersensitivity in mice immunized with high-dose sheep erythrocytes.
Tanouchi et al. Immunosuppressive and anti-proliferative effects of a macrotetrolide antibiotic, tetranactin.
Willenborg et al. Inhibition of adjuvant arthritis in the rat by phosphosugars and the α‐glucosidase inhibitor castanospermine
Miller et al. Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission
Drew et al. Levamisole-associated neutropenia and autoimmune granulocytotoxins.
Connolly et al. Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs
Woo et al. Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506.
Anderson et al. Antisperm antibody titres, immune complex deposition and immunocompetence in long-term vasectomized mice
Krähenbühl et al. Absence of homologous restriction factor does not affect CTL‐mediated cytolysis
Zulman et al. Levamisole maintains cyclophsophamide-induced remission in murine lupus erythematosus.